Exercise capacity in idiopathic pulmonary fibrosis: The effect of pulmonary hypertension-Reference-Cited by-同舟云学术

Exercise capacity in idiopathic pulmonary fibrosis: The effect of pulmonary hypertension

Published:2011-03-30 Issue:3 Volume:16 Page:451-458
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:

Author:

BOUTOU AFRODITI K,PITSIOU GEORGIA G.,TRIGONIS IOANNIS,PAPAKOSTA DESPINA,KONTOU PASCHALINA K.,CHAVOUZIS NIKOLAOS,NAKOU CHRYSANTHI,ARGYROPOULOU PARASKEVI,WASSERMAN KARLMAN,STANOPOULOS IOANNIS

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1843.2010.01909.x/fullpdf

Reference35 articles.

1. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis;Nadrous;Chest,2005

2. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant;Shorr;Eur. Respir. J.,2007

3. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis;Lettieri;Chest,2006

4. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis;Daniels;Eur. Respir. J.,2008

5. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots;Nathan;Am. J. Respir. Crit. Care Med.,2007

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxygen saturation recovery after 6-minute walk test in patients with idiopathic pulmonary fibrosis;BMC Pulmonary Medicine;2024-07-31

2. Pulmonary Hypertension Associated with Chronic Lung Disease;Current Respiratory Medicine Reviews;2024-05

3. Comprehensive approach to rehabilitation of patients with COVID-19. (A literature review);Problems of Balneology, Physiotherapy and Exercise Therapy;2024

4. Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients;Medicina;2023-12-28

5. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension;Pulmonary Circulation;2023-04